BESVIL TRIO 100 OCTACAPS 30'S

Besvil Trio 100 Octacaps 30'S is a medication that contains a combination of three medicines. It is used to treat type 2 diabetes mellitus.

Besvil Trio 100 Octacaps 30'S is used to control high blood sugar levels in people with type 2 diabetes mellitus.

The active ingredients in Besvil Trio 100 Octacaps 30'S are Metformin, Glimepiride and Voglibose.

Common side effects of Besvil Trio 100 Octacaps 30'S include nausea, vomiting, diarrhea, and abdominal pain.

The safety of Besvil Trio 100 Octacaps 30'S during pregnancy has not been established. It should only be used if clearly needed and under the supervision of a doctor.

Alcohol should be avoided while taking Besvil Trio 100 Octacaps 30'S as it can lower blood sugar levels and increase the risk of side effects.

Besvil Trio 100 Octacaps 30'S should be stored at room temperature, away from direct sunlight and moisture.

Yes, Besvil Trio 100 Octacaps 30'S can interact with certain other medications. Inform your doctor about all the medications you are taking.

If you miss a dose of Besvil Trio 100 Octacaps 30'S, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule.

Besvil Trio 100 Octacaps 30'S is recommended to be taken with food to minimize the chances of stomach upset.

Besvil Trio 100 Octacaps 30'S may cause weight gain in some patients. It is important to maintain a healthy diet and regular exercise.

Alternatives to Besvil Trio 100 Octacaps 30'S depend on the individual patient's condition. Consult your doctor for advice on other suitable medications.

Besvil Trio 100 Octacaps 30'S may cause dizziness or low blood sugar levels. It is not safe to drive if you experience any of these side effects.

The duration for which you should take Besvil Trio 100 Octacaps 30'S will be determined by your doctor. Always consult your doctor before stopping the medication.

Consult your doctor before taking Besvil Trio 100 Octacaps 30'S with other diabetes medications, as it may lead to low blood sugar levels or other side effects.

Besvil Trio is a triple‑combination inhalation medicine containing fluticasone furoate (an inhaled corticosteroid), umeclidinium (a long‑acting muscarinic antagonist), and vilanterol (a long‑acting beta2‑agonist). It is used for long‑term maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and may be used in selected adults with asthma when a triple combination is clinically appropriate. It is not intended for the immediate relief of acute breathlessness or sudden asthma or COPD attacks.

Besvil Trio works through three complementary mechanisms. Fluticasone furoate reduces airway inflammation and swelling, decreasing mucus and hyper‑responsiveness. Umeclidinium blocks muscarinic receptors in airway smooth muscle, providing long‑lasting bronchodilation by preventing cholinergic‑mediated bronchoconstriction. Vilanterol stimulates beta2‑adrenergic receptors, further relaxing bronchial smooth muscle and improving airflow. Together, these actions help keep the airways open over 24 hours, reduce symptoms such as breathlessness and cough, and lower the risk of COPD exacerbations.

No. Besvil Trio is a maintenance inhaler and must not be used for rapid relief of acute breathlessness, wheezing, or sudden asthma or COPD attacks. Its components act over many hours and are not suitable for immediate symptom relief. Patients should always have a separate, fast‑acting rescue inhaler (such as a short‑acting beta2‑agonist) available for sudden symptoms, as advised by their healthcare professional. Any increase in the need for rescue medication or sudden worsening of breathing requires prompt medical review.

Besvil Trio is generally designed for once‑daily use, but the exact dosing schedule, strength, and duration must be determined by your prescribing clinician based on your diagnosis, disease severity, and previous treatments. You should follow the instructions on your prescription label and the patient information leaflet, and never change the frequency or number of inhalations without medical advice. If you are unsure about your regimen, consult your doctor or pharmacist rather than adjusting the dose yourself.

Common side effects associated with triple inhaled therapy containing fluticasone furoate, umeclidinium, and vilanterol include throat irritation, hoarseness or voice changes, cough after inhalation, headache, nasopharyngitis (sore throat, runny or blocked nose), and oral candidiasis (thrush). Dry mouth, constipation, and urinary difficulties may occur due to the anticholinergic component. Some patients may experience palpitations, mild tremor, or nervousness related to the beta2‑agonist. Most side effects are mild and manageable, but persistent or troublesome symptoms should be discussed with a healthcare professional.

To lower the risk of oral candidiasis (thrush) and hoarseness associated with the inhaled corticosteroid component, you should rinse your mouth thoroughly with water and spit it out after each dose of Besvil Trio. Do not swallow the rinse water. If your device allows, using a correct inhalation technique to minimize deposition in the mouth and throat also helps. Regular dental and oral checks, good oral hygiene, and prompt reporting of white patches, soreness, or difficulty swallowing are important for early detection and management.

Besvil Trio should be used with caution in patients with significant cardiovascular disease, including ischaemic heart disease, arrhythmias, heart failure, or uncontrolled hypertension. The vilanterol component, like other long‑acting beta2‑agonists, can cause increases in heart rate, palpitations, or changes in blood pressure in some individuals. Umeclidinium may also have mild cardiovascular effects. Before starting therapy, your doctor will assess your cardiac history and current medications. If you experience chest pain, marked palpitations, severe dizziness, or fainting while using Besvil Trio, seek medical attention promptly.

You should not stop Besvil Trio abruptly without consulting your healthcare professional, even if your symptoms improve. COPD and chronic asthma are long‑term conditions, and maintenance therapy is often required to keep symptoms under control and reduce exacerbations. Sudden discontinuation may lead to worsening breathlessness, increased cough, or flare‑ups. Your doctor may periodically reassess your treatment and, if appropriate, adjust or step down therapy in a controlled manner rather than stopping it suddenly.

If you miss a dose of Besvil Trio, take it as soon as you remember on the same day, unless it is almost time for your next scheduled dose. If it is close to the next dose, skip the missed dose and continue with your regular dosing schedule. Do not take extra inhalations to make up for a missed dose, as this may increase the risk of side effects without additional benefit. If you frequently forget doses, discuss strategies for adherence with your healthcare provider.

Besvil Trio is not suitable for everyone. It should not be used by individuals with a known hypersensitivity to fluticasone furoate, umeclidinium, vilanterol, or any of the excipients in the product. It is not intended for the treatment of acute severe asthma or acute COPD exacerbations. Caution or specialist assessment is required in patients with significant cardiovascular disease, arrhythmias, uncontrolled hypertension, active or latent tuberculosis, serious untreated infections, narrow‑angle glaucoma, urinary retention, or severe hepatic impairment. Use in pregnancy, breastfeeding, children, or adolescents should be based on a careful risk–benefit assessment by a specialist.

Besvil Trio may be used alongside other inhaled medicines such as short‑acting bronchodilators for rescue use, but combining it with additional long‑acting beta2‑agonists or long‑acting muscarinic antagonists is generally avoided to reduce the risk of additive side effects. The overall inhaled corticosteroid burden should also be considered. Your doctor will decide which other inhalers, if any, are appropriate in your regimen. You should inform your healthcare provider about all inhaled and oral medicines you use, including over‑the‑counter products and herbal supplements, to avoid duplication and interactions.